VEGFA and diabetes mellitus: In patients receiving anti-VEGF, sustained AKI was associated with age > 60 year (HR 0.5; 95%CI 0.3 to 0.8; P = 0.007), type of cancer (HR 1.5; 95%CI 1.1 to 2.1 P = 0.013), baseline Salb > 35 g/l (HR 0.5; 95%CI 0.3 to 0.9; P = 0.027), diagnosis of pre-existing diabetes (HR 2.4; 95%CI 1.4 to 4.1; P = 0.001) and the presence of infection (HR 2.1; 95%CI 1.2 to 3.5; P = 0.006).